Research news
Global call launched to tackle retinal drug delivery challenges
May 20 2025
BioMed X and Boehringer Ingelheim are expanding their joint XSeed Labs incubator in Ridgefield, Connecticut, with the launch of a second research group focused on next-generation intraocular biologics.
The new initiative aims to address the need for longer-lasting treatments for retinal diseases - specifically reducing the burden of frequent intraocular injections. A global call for proposals invites researchers to develop novel biologic platforms that combine extended intraocular activity with deep retinal penetration.
The selected team will work independently on-site to explore new design principles, develop a high-throughput human in vitro model for screening candidate biologics, and validate the most promising leads in preclinical models.
“Our goal is to push the boundaries of biologics design in ophthalmology,” said Mark Johnston, CEO of BioMed X USA. “This collaboration brings academic creativity into direct alignment with pharmaceutical innovation.”
The call is open to early-career researchers with expertise in ophthalmology, tissue engineering, or antibody discovery. Proposals must be submitted by 12 July 2025, via the BioMed X Career Space.
More information online
Digital Edition
ILM Guide 2025/26
June 2025
Buyers' Guide Listings- Product Listings by Category- Suppliers Listings (A-Z)Chromatography Articles- Setting the power coefficient and the baseline to linearise the signal of the evaporative ligh...
View all digital editions
Events
Jun 15 2025 Bruges, Belgium
Jun 18 2025 London, UK
Jun 24 2025 Warsaw, Poland
Jun 24 2025 Shanghai, China
Discovery & Development Europe 2025
Jul 01 2025 Basel, Switzerland